- Home
- CANF vs LRHC Comparison
CANF vs LRHC Comparison
Compare CANF & LRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- LRHC
- Stock Information
- Founded
- CANF 1994
- LRHC 2004
- Country
- CANF Israel
- LRHC United States
- Employees
- CANF N/A
- LRHC N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- LRHC
- Sector
- CANF Health Care
- LRHC
- Exchange
- CANF Nasdaq
- LRHC Nasdaq
- Market Cap
- CANF 14.4M
- LRHC 13.7M
- IPO Year
- CANF N/A
- LRHC 2023
- Fundamental
- Price
- CANF $1.48
- LRHC $0.81
- Analyst Decision
- CANF Strong Buy
- LRHC
- Analyst Count
- CANF 2
- LRHC 0
- Target Price
- CANF $14.00
- LRHC N/A
- AVG Volume (30 Days)
- CANF 1.2M
- LRHC 138.5K
- Earning Date
- CANF 12-31-2024
- LRHC 11-20-2024
- Dividend Yield
- CANF N/A
- LRHC N/A
- EPS Growth
- CANF N/A
- LRHC N/A
- EPS
- CANF N/A
- LRHC N/A
- Revenue
- CANF $667,000.00
- LRHC $63,172,153.00
- Revenue This Year
- CANF $409.56
- LRHC N/A
- Revenue Next Year
- CANF N/A
- LRHC N/A
- P/E Ratio
- CANF N/A
- LRHC N/A
- Revenue Growth
- CANF N/A
- LRHC 140.04
- 52 Week Low
- CANF $1.29
- LRHC $0.47
- 52 Week High
- CANF $4.69
- LRHC $5.50
- Technical
- Relative Strength Index (RSI)
- CANF 35.58
- LRHC 62.52
- Support Level
- CANF $1.30
- LRHC $0.67
- Resistance Level
- CANF $1.72
- LRHC $0.72
- Average True Range (ATR)
- CANF 0.18
- LRHC 0.06
- MACD
- CANF -0.01
- LRHC 0.01
- Stochastic Oscillator
- CANF 17.92
- LRHC 85.70
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has five reportable segments namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management and Real Estate Brokerage Services (Commercial). It derives maximum revenue from Real Estate Brokerage Services (Residential) segment.